JAK INHIBITOR FOR REVERSAL OF IMMUNE CHECKPOINT INHIBITOR DIABETES

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Phase
Phase 1

Eligibility

Minimum Age
N/A
Maximum Age
N/A
Share:
Study Stats
Protocol No.
25-0569
Category
Breast Cancer
Colorectal Cancer
Liver Cancer
Lung Cancer
Pancreatic Cancer
Prostate Cancer
Stomach Cancer
Contact
Christy Sidhu